Impact of LOFT Therapy™ on Breast Cancer Survivors: A Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Kathy Miller
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
研究概览
简要总结
The purpose of this study is to evaluate the safety and feasibility of LOFT Therapy in breast cancer survivors. In a previous study, the investigators found that many patients are more debilitated at diagnosis than previously recognized. Both chemotherapy and anti-estrogen therapy have a large effect. Within 6 months patients replace muscle with fat leading to a significant reduction in muscle power and endurance. Our data suggests that common exercise recommendations for at least 150 minutes of exercise a week would be far beyond many of our patients' physical ability after therapy, leading to the soreness, injury, frustration, and early discontinuation (or failure to initiate an exercise program in the first place). The degree of muscle loss seen in our patients is similar to that documented in US astronauts after long-term space flight. Our collaborator Dr. Yvonne Cagle, retired USAF flight surgeon, noted that the cosmonauts were in better shape (had less muscle atrophy) than the astronauts. This difference was more than could be explained by the rigorous Russian exercise program. The only key distinction was the compressive, "penguin suits" used by the Russians. This observation lead Dr. Cagle to develop a technique called low intensity, off loaded-compressive therapy (LOFT) to replicate the impact of the Russian penguin suits for patients who were debilitated, whether by space flight or by chronic conditions such as arthritis, Parkinson's disease, and multiple sclerosis. The LOFT method does not require excessive exertion or strain on the joints. In field observations, LOFT therapy improved muscle strength, muscle mass, endurance, sleep quality, and fatigue. This pilot study is the first to evaluate the safety, feasibility, and biologic impact of LOFT on breast cancer survivors.
详细描述
Objectives This pilot trial will provide feedback on the feasibility and impact of LOFT in breast cancer survivors. The investigators will also explore the relationship of the LOFT intervention to changes in insulin resistance, growth hormone levels, body mass index, patient reported physical activity, fatigue, and overall quality of life.
Primary Objective Evaluate the safety and feasibility of LOFT training in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy.
Secondary Objectives
- Estimate the effect size of LOFT training on muscle power, endurance, daily activity, fatigue, and quality of life.
- Estimate the effect of short-term LOFT training on biochemical parameters of inflammation, metabolism, anabolic hormone secretion, and bone turnover.
LOFT Therapy™ Summary LOFT Therapy™ is a form of exercise that requires less energy for movement. LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with stage 0-III breast cancer within the past 3 years
- •Must have completed local therapy for their breast cancer
- •Must have received systemic therapy for their breast cancer (anti-estrogen and/or chemotherapy)
- •Chemotherapy must be complete prior to entry
- •Anti-estrogen therapy may be ongoing
- •Ambulatory without assistive devices
- •No orthopedic restrictions or neurologic deficits that would limit ability to complete the Power Protocol (based on the opinion of the investigator)
- •No requirement for supplemental O2
- •No unstable angina, regular use of nitroglycerin for exertional angina, or MI within the last 12 months
- •No local or distant recurrence of their breast cancer
- •No active lymphedema
- •No history of hemorrhagic stroke
- •No Heparin or Coumadin Use
- •No symptomatic peripheral vascular obstructions
- •No active gallbladder disease
- •No active kidney stones
- •No active gout
- •No active diverticulitis
- •No pituitary diseases or growth
- •Able to provide written informed consent and authorization for release of health information
- •Able to commit to LOFT training 2 times/week for 4 weeks
排除标准
- •Inability to meet one of the inclusion criteria above.
研究组 & 干预措施
LOFT Therapy
LOFT therapy twice weekly for 4 weeks
干预措施: LOFT Therapy (Other)
结局指标
主要结局
Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
时间窗: Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline)
Analysis of the modified intent-to-treat population defined as patients with at least 1 post-baseline measurement as well as eligible patients who decline participation, reason for refusal, and number of enrolled patients who do not complete all LOFT training sessions
次要结局
- Safety of LOFT intervention in this population patient reported adverse events(Assessed at each session and throughout the intervention)
- Heart rate(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Power per body weight (muscle power)(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Endurance(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Daily activity(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Fatigue(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Quality of life(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Biochemical parameters of chronic inflammation(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Biochemical parameters of metabolism and insulin homeostasis(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Anabolic hormone secretion(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
- Biochemical parameters of bone turnover(Change from pre-LOFT therapy (baseline) to post-LOFT therapy (5 weeks after baseline))
研究者
Kathy Miller
Professor of Medicine and Sheila D. Ward Scholar
Indiana University School of Medicine